• SPX
  • $5,964.07
  • 0.26 %
  • $15.36
  • DJI
  • $44,204.66
  • 0.76 %
  • $334.30
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $18,987.91
  • 0.08 %
  • $15.49
PureTech Health plc (PRTC) Stock Price, News & Analysis

PureTech Health plc (PRTC) Stock Price, News & Analysis

Currency in USD Disclaimer

$22.13

$0.82

(3.82%)

Day's range
$21.41
Day's range
$23.5
50-day range
$19.02
Day's range
$23.5
  • Country: US
  • ISIN: US7462371060
52 wk range
$17.08
Day's range
$34
  • CEO: Dr. Bharatt M. Chowrira J.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 1.31
  • Piotroski Score 1.00
  • Grade Overweight
  • Symbol (PRTC)
  • Company PureTech Health plc
  • Price $22.13
  • Changes Percentage (3.82%)
  • Change $0.82
  • Day Low $21.41
  • Day High $23.50
  • Year High $34.00

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 04/23/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $57.00
  • High Stock Price Target $70.00
  • Low Stock Price Target $44.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.40
  • Trailing P/E Ratio -12.47
  • Forward P/E Ratio -12.47
  • P/E Growth -12.47
  • Net Income $-65,697,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

PureTech Health plc Frequently Asked Questions

  • What is the PureTech Health plc stock price today?

    Today's price of PureTech Health plc is $22.13 — it has increased by +3.82% in the past 24 hours. Watch PureTech Health plc stock price performance more closely on the chart.

  • Does PureTech Health plc release reports?

    Yes, you can track PureTech Health plc's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the PureTech Health plc stock forecast?

    Watch the PureTech Health plc chart and read a more detailed PureTech Health plc stock forecast to see what analysts suggest you do with its shares.

  • What is PureTech Health plc stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by PureTech Health plc stock ticker.

  • How to buy PureTech Health plc stocks?

    Like other stocks, PRTC shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is PureTech Health plc's EBITDA?

    PureTech Health plc measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in PureTech Health plc’s financial statements.

  • What is the PureTech Health plc's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -19.7288288288, which equates to approximately -1,972.88%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in PureTech Health plc stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including PureTech Health plc's financials relevant news, and technical analysis. PureTech Health plc's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for PureTech Health plc stock currently indicates a “sell” signal. For more insights, review PureTech Health plc’s technical analysis.

  • A revenue figure for PureTech Health plc for its last quarter?

    PureTech Health plc published it's last quarterly revenues at $144,000.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.